Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Otamixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 18/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 0.81 |
| ▸ | PLG | P00747 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otamixaban SCHEMBL12447697 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL29426323 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL12589586 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL16588897 | 0.99 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL7890763 | 0.99 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL12805269 | 0.93 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL15489295 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL14542917 | 0.92 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL13160832 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL19222680 | 0.92 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12514871-B2 | Pegylated menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025262269-A1 | MONITORING OF REVERSAL AGENTS FOR ANTICOAGULANTS | ENZYRE B.V. (NL) | 2025-12-26 | — | — | WO | claimed |
| WO-2025150072-A1 | A STABLE ORAL PRO-DISPERSION FORMULATION AND IMPLEMENTATIONS THEREOF | PULSE PHARMACEUTICALS PVT LTD (IN) | 2025-07-17 | — | — | WO | claimed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | claimed |
| US-9492437-B2 | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | SANOFI (FR) | 2016-11-15 | — | — | US | claimed |
| US-20150202190-A1 | Otamixaban for Use in the Treatment of Non-ST Elevation Acute Coronary Syndrome in Patients Planned to Undergo Coronary Artery Bypass Grafting | SANOFI (FR) | 2015-07-23 | — | — | US | claimed |
| EP-2890381-A1 | OTAMIXABAN FOR USE IN THE TREATMENT OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS PLANNED TO UNDERGO CORONARY ARTERY BYPASS GRAFTING | SANOFI (FR) | 2015-07-08 | — | — | EP | claimed |
| US-8993602-B2 | Benzoic acid salt of otamixaban | SANOFI (FR) | 2015-03-31 | — | — | US | claimed |
| EP-2691371-B1 | BENZOIC ACID SALT OF OTAMIXABAN | SANOFI SA (FR) | 2015-03-18 | — | — | EP | claimed |
| WO-2014033221-A1 | OTAMIXABAN FOR USE IN THE TREATMENT OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS PLANNED TO UNDERGO CORONARY ARTERY BYPASS GRAFTING | SANOFI (FR) | 2014-03-06 | — | — | WO | claimed |
| US-20120238605-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | SANOFI (FR) | 2012-09-20 | — | — | US | claimed |
| EP-2459193-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | SANOFI (FR) | 2012-06-06 | — | — | EP | claimed |
| WO-2011012527-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | WO | claimed |
| WO-2006110726-A2 | DOSAGE FORMULATIONS AND METHODS OF TREATMENT AND PREVENTION | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | SERPINC1, F2, F8 | F10 6/4885PRSS1 149/4885TMPRSS2 437/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885PRSS1 311/4885TMPRSS2 870/4885 |
| US-20150202190-A1 | Otamixaban for Use in the Treatment of Non-ST Elevation Acute Coronary Syndrome in Patients Planned to Undergo Coronary Artery Bypass Grafting | TNNI3, PCSK9, TNNT2 | F10 22/4885PRSS1 194/4885TMPRSS2 195/4885 |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | SGMS1, SGMS2, MEN1 | F10 1095/4885PRSS1 3346/4885TMPRSS2 3851/4885 |
| US-20120238605-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | TNNI3, MB, ABAT | F10 460/4885PRSS1 2617/4885TMPRSS2 1706/4885 |
| US-12605371-B2 | Combination therapy for cancer | BRAF, TFPI, HGFAC | F10 42/4885PRSS1 311/4885TMPRSS2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.